Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis, Comprehensive Landscape, Current And Future Growth By Forecast To 2024

Market Research Future published a Cooked research report on “Global Genetic Testing Market Research Report, forecast to 2024” – Market Size, Share, Growth, Analysis, Regional Outlook, Scope, Stake, Progress, Trends.

Genetic Testing Market Analysis

Genetic testing is the study of genes inherited from one’s parents with the help of laboratory methods. The test is conducted to identify the risk of health problems, to assess response to treatment, and to identify health risks in advance. The study undertaken by the team of Market Research Future reveals that the global genetic testing market is projected to reach a valuation of USD 10,033.4 million by the end of the forecast period in 2023 from its last calculated valuation of USD 4,683 in 2016. The growth of the market is calculated to be at a rate of 9.8% during the forecast period.

It is reported that genetic testing has gained increasing traction and popularity in recent years for its capability of detecting and preventing genetic diseases, cancer, and so on. The growth of the market is identified to be the increasing consumer awareness concerning the early diagnosis of diseases as well as the rising expenditure on various preventive measures. The technological advancements introduced or slated to be introduced offers the market with enhanced opportunity to improve the efficiency and accuracy of the study. This, in turn, ameliorates the overall market of genetic testing. Also, the adoption of non-invasive genetic testing technology is also expected to push the growth of the market during the forecast period.

Genetic Testing Market Segmentation

The global genetic testing market segmentation is divided on the basis of four key dynamics:

By type, the market includes direct to consumer (DTC) genetic testing and prescribed genetic testing. Herein, the prescribed genetic testing segment held the largest share of the market as per the study conducted in 2016. The prescribed genetic testing segment held a staggering 97% of the market to its name. The segment is expected to continue its unprecedented dominance in the forthcoming years as well.

By method, the market includes Chromosomal Genetic Test, Molecular Genetic Test/ DNA Test, and Biochemical Genetic Test. The molecular genetic test/DNA test segment held the largest percentage of the market and is expected to expand further in the coming years.

By type of test, the genetic testing market includes Predictive Test, Family DNA Test, Diagnostic Test, and others. The diagnostic test segment dominates the category as the leading market share holder and is anticipated to held on to the same during the forecast period.

By indication, the market comprises of Autoimmune Disorder Testing, Neurogenetic Disorder Testing, Cancer Testing, Muscular dystrophies, and others. The cancer testing segment held the largest share of the market and is expected to retain its position in the forthcoming years of the forecast period.

Genetic Testing Market Regional Analysis

The global genetic testing market is regionally segmented into the following regions: America, Asia Pacific, Europe, and the Middle East & Africa.

Geographically, the market is led by the Americas with approximately 46.3% of the share tit its name. The growth and global positioning of the region can be attributed to the high awareness concerning genetic testing, continuous innovation, and fast-paced adoption of new and advancing technology. In this region, the US holds a majority of the market share and contributes significantly to the dominance of the North American region.

The European region holds the second spot in the global standings for genetic testing. The regional market is expected to reach a valuation of USD 2,553.10 million by the end of the forecast period in 2023. Whereas, the Asia Pacific region is expected to be the fastest growing market for genetic testing and is calculated to grow at a CAGR of 10.1% during the forecast period. The Middle Eastern and African is slated to attain limited growth during the forthcoming years owing to lack of awareness and lack of established infrastructure.

Genetic Testing Market Competitive Landscape

The global genetic testing market holds a number of key players, including QIAGEN N.V. (Germany), Abbott Laboratories (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Quest Diagnostics (U.S.), Myriad Genetics (U.S.), Illumina Inc. (U.S.), and PerkinElmer Inc. (U.S.).

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/genetic-testing-market-2009

Genetic Testing Industry News

March 28th, 2019, Dana-Farber Cancer Institute announced the world’s first ever Lynch Syndrome Center to support families and patients with inherited condition.

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

Australia Institute found men benefit from tax cuts if brought forward by Treasurer Josh Frydenberg | Daily Mail Online
 
Advertisement

REVEALED: The group that will benefit the most from economy boosting tax cuts - and it's bad news for women

  • Treasurer Josh Frydenberg indicated tax cuts could be part of delayed budget
  • Men on high incomes would be main beneficiaries if tax cuts brought forward
  • If cut for 2022 moved for every dollar of relief women would get, men get double

Men on high incomes would be the main beneficiaries if already legislated tax cuts are brought forward as flagged by the federal government, new modelling suggests.

The study by the Australia Institute think tank found if the tax cuts scheduled from 2022/23 are introduced earlier, for every dollar of tax cut that women would get, men would get $2.28.

If at the same time tax cuts planned from 2024/25 are also brought forward, men would get $2.19 for every dollar a woman would get.

Previous modelling by the institute showed higher earners would benefit more from these tax cuts, and are more likely to save the benefit than spend it.

Treasurer Josh Frydenberg (pictured) has indicated these tax cuts could form part of his delayed 2020/21 budget, which will be handed down on October 6

Treasurer Josh Frydenberg (pictured) has indicated these tax cuts could form part of his delayed 2020/21 budget, which will be handed down on October 6

The study by the Australia Institute think tank found if the tax cuts scheduled from 2022/23 are introduced earlier, for every dollar of tax cut that women would get, men would get $2.28 (stock)

The study by the Australia Institute think tank found if the tax cuts scheduled from 2022/23 are introduced earlier, for every dollar of tax cut that women would get, men would get $2.28 (stock)

'Giving tax cuts to the wealthy will have a very limited stimulatory effect on the broader economy, but it will significantly widen the economic divide that already exists between men and women in this country,' the institute's senior economist Matt Grudnoff said.

The institute says women have been the hardest hit during the COVID-19 pandemic in terms of lost employment.

It said in March and April, employment fell 3.9 per cent for men, but 5.3 per cent for women.

'Despite women facing a bigger impact from the COVID-19 recession, government stimulus has focused heavily on male-dominated industries such as construction,' Mr Grudnoff said.

'Rather than spending billions of dollars bringing forward tax cuts that mainly go to men on high incomes, the government could better target that stimulus.'

He said investing in employment-intensive industries like healthcare, aged care and education will be more efficient than bringing forward the tax cuts, and would create more jobs for every million dollars of stimulus.

Previous modelling by the institute showed higher earners would benefit more from these tax cuts, and are more likely to save the benefit than spend it (stock)

Previous modelling by the institute showed higher earners would benefit more from these tax cuts, and are more likely to save the benefit than spend it (stock)

'These industries also employ large numbers of Australian women who have been disproportionately affected by the COVID-19 recession,' he said.

Treasurer Josh Frydenberg has indicated these tax cuts could form part of his delayed 2020/21 budget, which will be handed down on October 6.

He has argued bringing forward these tax cuts would benefit the economy by triggering household spending. 

There are several changes due in the 2022/23 tax cuts, including an increase in the threshold of the 32.5 cent bracket from $37,000 to $45,000 and the threshold of the 37 cent bracket from $90,000 to $120,000.

In 2024/25, the tax cuts reduce the 32.5 cent rate to 30 cents.

Australia Institute found men benefit from tax cuts if brought forward by Treasurer Josh Frydenberg

The comments below have not been moderated.

The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.

What's This?

By posting your comment you agree to our house rules.

More top stories

Bing
Advertisement
   

DON'T MISS

Advertisement
   

more don'T MISS

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
 

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

भारत ने खोली पाक की कलई: आतंकवाद का केंद्र मानवाधिकार पर न बोले

भारत ने खोली पाक की कलई: आतंकवाद का केंद्र मानवाधिकार पर न बोले

भारत ने एक बार फिर अंतरराष्ट्रीय मंच पर पाकिस्तान की कलई खोलते हुए उसे आतंकवाद का केंद्र बताया है। भारत ने पाकिस्तान पर बड़ा हमला करते हुए कहा

Published by Roshni Khan Published: September 16, 2020 | 10:33 am
pakistan

भारत ने खोली पाक की कलई: आतंकवाद का केंद्र मानवाधिकार पर न बोले (social media)

नई दिल्ली: भारत ने एक बार फिर अंतरराष्ट्रीय मंच पर पाकिस्तान की कलई खोलते हुए उसे आतंकवाद का केंद्र बताया है। भारत ने पाकिस्तान पर बड़ा हमला करते हुए कहा कि उसे मानवाधिकार पर व्याख्यान देने का हक नहीं है क्योंकि उसने लगातार जातीय और हिंदुओं, सिखों और ईसाइयों समेत अन्य धार्मिक अल्पसंख्यकों को प्रताड़ित करने में कोई कसर नहीं छोड़ी है।

ये भी पढ़ें:कोविड-19 पर राज्यसभा में चर्चा के लिए RJD सांसद मनोज झा ने नोटिस दिया

कुत्सित इरादों को पूरा करने में जुटा है पाक

जिनेवा में मानवाधिकार परिषद के 45वें सत्र के दौरान पाकिस्तान की ओर से की गई टिप्पणी के जवाब में भारत की ओर से पाकिस्तान पर बड़ा हमला बोला गया। जवाब देने के अपने अधिकार का इस्तेमाल करते हुए भारतीय प्रतिनिधि ने पाकिस्तान की कलई खोलकर रख दी।

भारत ने कहा कि पाकिस्तान झूठे और मनगढ़ंत आरोप लगाकर अपने कुत्सित इरादों को पूरा करने में लगा हुआ है। अंतरराष्ट्रीय मंचों पर भारत को बदनाम करने की उसकी पुरानी आदत है।

पाक में धार्मिक अल्पसंख्यकों का उत्पीड़न

भारतीय प्रतिनिधि इंद्रमणि पांडेय ने कहा कि भारत और दुनिया के अन्य देशों को पाकिस्तान जैसे देश से मानवाधिकार पर व्याख्यान सुनने की जरूरत नहीं है। पाकिस्तान ऐसा देश है जो लगातार जातीय और धार्मिक अल्पसंख्यकों को प्रताड़ित करने में जुटा हुआ है।

पाकिस्तान आतंकवाद का बड़ा केंद्र बन चुका है और इस देश के प्रधानमंत्री ने जम्मू कश्मीर में लड़ाई के लिए हजारों आतंकियों को प्रशिक्षण देने की बात गर्व के साथ स्वीकार की है।

pakistan
pakistan (social media)

पाक से आतंकी गतिविधियों का संचालन

उन्होंने कहा कि संयुक्त राष्ट्र की प्रतिबंधित सूची में शामिल तमाम आतंकवादी पाकिस्तान से अपनी आतंकी गतिविधियों का संचालन कर रहे हैं और पाकिस्तान सरकार की ओर से उन्हें पूरी मदद दी जा रही है। पाकिस्तान जैसे देश को मानवाधिकारों पर दुनिया के दूसरे देशों को प्रवचन नहीं देना चाहिए।

भारत ने कहा कि पाकिस्तान जम्मू कश्मीर में आतंकियों की घुसपैठ कराने के साथ ही लोकतांत्रिक प्रक्रिया को पटरी से उतारने की लगातार साजिश रच रहा है। इसके बावजूद भारत की ओर से जम्मू कश्मीर में जमीनी स्तर पर लोकतंत्र को पुनर्जीवित किया गया है और यहां सामाजिक और आर्थिक विकास को रफ्तार दी गई है।

भारत मानवाधिकारों के प्रति प्रतिबद्ध

मानवाधिकार परिषद के 45वें सत्र के दौरान भारत के स्थायी प्रतिनिधि इंद्रमणि पांडेय ने संयुक्त राष्ट्र मानवाधिकार प्रमुख मिशेल बेचलेट के क्षेत्र के बारे में दिए गए बयान पर खेद जताया। भारत के प्रतिनिधि ने कहा कि हमारा देश मानवाधिकारों को बरकरार रखने के लिए पूरी तरह प्रतिबद्ध है।

उन्होंने कहा कि देश की संप्रभुता, क्षेत्रीय अखंडता और आंतरिक मामलों में दखल नहीं दिया जाना चाहिए। मानवाधिकार के एजेंडे पर बहस निष्पक्ष और पारदर्शी तरीके से की जानी चाहिए।

ये भी पढ़ें:कोरोना के मरीज 50 लाख पार, जंग जीतने वालों में सबसे आगे हिंदुस्तानी

जम्मू-कश्मीर का विशेष तौर पर जिक्र

भारत की ओर से जम्मू-कश्मीर को विशेष दर्जा देने वाले अनुच्छेद 370 का भी उल्लेख किया गया। भारत ने कहा कि अनुच्छेद 370 के प्रावधानों को पिछले साल खत्म कर दिया गया है।

जम्मू-कश्मीर में किए गए इस बदलाव की वजह से अब इस क्षेत्र के लोग उन मूलभूत अधिकारों को हासिल करने में कामयाब हुए हैं जो भारत के अन्य हिस्सों के लोगों को हासिल है। उन्होंने कहा कि भारत ने काफी सोच समझकर यह कदम उठाया है और अब इस केंद्र शासित प्रदेश में विकास और तरक्की की रफ्तार में तेजी आई है।

दोस्तों देश दुनिया की और खबरों को तेजी से जानने के लिए बनें रहें न्यूजट्रैक के साथ। हमें फेसबुक पर फॉलों करने के लिए @newstrack और ट्विटर पर फॉलो करने के लिए @newstrackmedia पर क्लिक करें।

न्यूजट्रैक के नए ऐप से खुद को रक्खें लेटेस्ट खबरों से अपडेटेड । हमारा ऐप एंड्राइड प्लेस्टोर से डाउनलोड करने के लिए क्लिक करें - Newstrack App

    Tags:

और ख़बरें

यह भी पढ़ें

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

Serum Institute Gets Nod To Resume Oxford COVID-19 Vaccine Trial In India

Serum Institute Gets Nod To Resume Oxford COVID-19 Vaccine Trial In India

Serum Institute of India has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.

Serum Institute Gets Nod To Resume Oxford COVID-19 Vaccine Trial In India

SII has partnered with AstraZeneca for manufacturing vaccine candidate for COVID-19 (Representational)

New Delhi:

Drugs Controller General of India (DCGI) Dr VG Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford COVID-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.

The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be "scrupulously" followed by Serum Institute of India (SII).

SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.

The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford COVID-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of "an unexplained illness" in a participant in the study.

On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine have resumed in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.

SII, which has partnered with AstraZeneca for manufacturing the vaccine candidate for COVID-19, on Tuesday submitted the recommendations of the Data and Safety Monitoring Board (DSMB), UK and DSMB, India, and requested for permission to restart enrolment in the clinical trial.

According to Tuesday's order issued by DCGI, the DSMB, UK, recommended that the investigators recommence all immunization in their clinical trials subject to certain conditions.

DSMB, India, also has recommended to continue the study and enroll the remaining participants in the clinical trial as per protocol subject to certain conditions.

According to the order, SII has submitted revised participant information sheet, revised informed consent form and additional safety monitoring plan for the evolved participants.

The Pune-based firm has also submitted a summary of safety follow up of seven days post first vaccination, stating that no serious adverse events were experienced by any of the subjects till the date of the reporting, and the reported adverse events were stated to be mild, resolved on their own and did not have any sequale.

"In view of the above, I Dr V G Somani, Drugs Controller General of India, Central Licensing Authority, after careful examination of your reply and the recommendations of the DSMB in India and in UK revoke herewith the order dated September 11 issued under Rule 30 of the New Drugs and Clinical Trials Rules, 2019.

"You may recommence the clinical trial as recommended by DSMB, India, as per already approved protocol and the provisions laid down under the New Drugs and Clinical Trial Rules, 2019, subject to the conditions mentioned," the order said.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

World Shares Mixed, US Futures Gain Ahead Of Fed Statement
2-MIN READ

World Shares Mixed, US Futures Gain Ahead Of Fed Statement

A currency trader watches computer monitors near screens showing the Korea Composite Stock Price Index (KOSPI), left, and the foreign exchange rate between U.S. dollar and South Korean won at the foreign exchange dealing room in Seoul, South Korea, Wednesday, Sept. 16, 2020. Shares were mostly higher in Asia on Wednesday after advances for big technology companies carried Wall Street to further gains overnight. (AP Photo/Lee Jin-man)

A currency trader watches computer monitors near screens showing the Korea Composite Stock Price Index (KOSPI), left, and the foreign exchange rate between U.S. dollar and South Korean won at the foreign exchange dealing room in Seoul, South Korea, Wednesday, Sept. 16, 2020. Shares were mostly higher in Asia on Wednesday after advances for big technology companies carried Wall Street to further gains overnight. (AP Photo/Lee Jin-man)

World markets were mixed ahead of the Federal Reserves policy announcement on Wednesday while U.S. futures edged higher.

  • Last Updated: September 16, 2020, 2:24 PM IST

World markets were mixed ahead of the Federal Reserves policy announcement on Wednesday while U.S. futures edged higher.

Benchmarks rose modestly in Frankfurt and Tokyo but slipped in London and Hong Kong.

Investors are awaiting the outcome of the U.S. Federal Reserve policy meeting later Wednesday. It is expected to keep the benchmark rate at nearly zero for some time to help the economy recover from the pandemic downturn.

The U.S. central bank’s statement might change some of the language around its existing pledge to buy bonds to support markets, economists say.

Japans central bank has begun a policy meeting that will wrap up Thursday but also is not expected to result in any major changes.

Germany’s DAX was less than 0.1% higher at 13,223.43 while the CAC 40 in France was flat, at 5,067.95. The FTSE 100 in Britain edged 0.1% lower to 6,101.31. The futures for the S&P 500 and for the Dow industrials both gained 0.2%.

Japan reported that its trade balance swung into surplus in August as a 15% decline in exports from a year earlier was outpaced by a 21% drop in imports. Exports have been hammered by the coronavirus pandemic but the rate of decline has been narrowing over the past several months as shutdowns eased and the Chinese economy began to recover from a sharp downturn in early spring.

Japan’s long-serving prime minister, Shinzo Abe, resigned as of Wednesday and was replaced by his chief cabinet secretary, Yoshihide Suga. Suga has said he intends to push ahead with Abe’s policies and little change is expected for the world’s third-largest economy.

Tokyo’s Nikkei 225 edged 0.1% higher to 23,475.53 while the Hang Seng in Hong Kong was almost unchanged at 24,725.63. South Korea’s Kospi gave up 0.3% to 2,435.92 and the S&P/ASX 200 in Sydney jumped 1% to 5,956.10. The Shanghai Composite index slipped 0.4% to 3,283.92.

India’s Sensex edged 0.4% higher to 39,182.12 even as the number of the country’s confirmed coronavirus cases jumped to nearly 5 million, second only to the U.S. case count of 6.6 million, according to a tally by Johns Hopkins University. The actual number of cases is thought to be much higher.

On Tuesday, the S&P 500 rose 0.5% to 3,401.20 after gaining more than 1% earlier in the session, its second straight sizable gain following the benchmark’ index’s worst week since June.

Big Tech stocks have been bouncing back this week after suddenly losing altitude earlier this month amid worries that their prices had climbed too high.

Analysts expect more volatility for stocks in the months ahead as the market navigates uncertainty over the outcome of the election, pessimism that Democrats and Republicans in Washington will be able to reach a deal to send more aid to unemployed workers and an economy still struggling amid the pandemic.

Treasury yields were relatively steady. The yield on the 10-year Treasury was unchanged at 0.67%.

In other trading, U.S. benchmark crude oil rose 87 cents to $38.15 per barrel in electronic trading on the New York Mercantile Exchange. It surged $1.02 on Tuesday to $38.28 per barrel.

Brent crude, the international standard, picked up 82 cents to $41.35 per barrel.

The dollar fell to 105.21 Japanese yen from 105.43 yen late Tuesday. The euro climbed to $1.1865 from $1.1848.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Next Story
Loading

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

Share this Comment:

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

Pfizer Says Late-stage Coronavirus Vaccine Study Shows Moderate Side Effects
1-MIN READ

Pfizer Says Late-stage Coronavirus Vaccine Study Shows Moderate Side Effects

Representational Image: Reuters

Representational Image: Reuters

Pfizer Inc said on Tuesday participants were showing mildtomoderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing latestage study.

  • Last Updated: September 16, 2020, 8:35 AM IST

Pfizer Inc said on Tuesday participants were showing mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.

Over 12,000 study participants had received a second dose of the vaccine, Pfizer executives said on an investor conference call.

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.

Pfizer said it was continuously scrutinizing the safety and tolerability of the vaccine in its study.

An independent data monitoring committee could recommend pausing the study at any time, but has not done so till date, the company said.

The comments follow rival AstraZeneca’s COVID-19 vaccine trials being put on hold worldwide on Sept. 6 after a serious side effect was reported in a volunteer in Britain.

AstraZeneca’s trials resumed in Britain and Brazil on Monday following the green light from British regulators, but remain on hold in the United States.

Next Story
Loading

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

Insidious and Rabid to Target One Community in TV Shows, Observes SC; Stays Broadcast of Programme
3-MIN READ

Insidious and Rabid to Target One Community in TV Shows, Observes SC; Stays Broadcast of Programme

Supreme Court. (Image for representation/AFP)

Supreme Court. (Image for representation/AFP)

The bench was emphatic that such programmes that tend to show a particular community in bad light cannot go without scrutiny just by claiming the right to free speech and free press.

The Supreme Court on Tuesday described as "insidious" and "rabid" efforts to target a particular community through TV shows.

A bench of Justices DY Chandrachud and KM Joseph expressed deep concern on use of power and reach of electronic media to attack a particular community as it heard a petition against a TV show by a private channel on the entry of Muslims in civil services.

"As the Supreme Court of this nation, we can't allow you to say that Muslims are infiltrating civil services. We can't tolerate this. No one can say journalists have absolute freedom to say anything," observed the bench as it issued an interim order on staying the telecast of subsequent episodes of the programme.

The court restrained Sudarshan TV from telecasting two episodes of 'Bindas Bol' programme, scheduled for Tuesday and Wednesday, saying it prime facie appears to vilify the Muslim community.

The bench was emphatic that such programmes that tend to show a particular community in bad light cannot go without scrutiny just by claiming the right to free speech and free press.

The court called out the channel, saying it might be doing a disservice to the nation by not accepting India is a melting point of diverse culture. "Your client needs to exercise his freedom with caution," the bench told senior lawyer Shyam Divan who was appearing for the channel.

"It appears to the court that object of the programme is to vilify the Muslim community and make it responsible for an insidious attempt to infiltrate the civil services. We are duty bound to ensure adherence to the program code formed under Cable TV Act," said the bench in its order. It added that the edifice of a stable democratic society and observance of constitutional rights and duties is based on coexistence of communities. "Any attempt to vilify a community must be viewed with disfavour," it said.

The court was of the view that electronic media, because of its huge access, can become a focal point for destabilising the nation by targeting particular communities, and so certain standards should guide them.

"Reputations can be damaged, images can be tarnished. How to control this? State cannot do this. This is a very difficult area of regulation undoubtedly, but we are trying to spread a wider auspice of dialogue. Look at this program Solicitor, how rabid can it get? Targeting a community who are appearing for Civil services," Justice Chandrachud asked Solicitor General Tushar Mehta.

On his part, Justice KM Joseph said, "We need to look at the ownership of the visual media. Entire shareholding pattern of the company must be on site for the public. Revenue model of that company should also be put up to check if the government is putting more ads in one and less in another."

But Mehta objected to the idea of external regulations on the media. "Freedom of the journalist is supreme. There are two aspects of the statements by Justice Joseph. It would be disastrous for any democracy to control the press. There is also a parallel media other than electronic media where a laptop and a journalist can lead to lakhs of people viewing their content. There are a large number of web portals whose ownership is different from what they show," he pointed out.

The law officer also cited an illustration of YouTube, saying how it will be possible to either regulate this platform or question its revenue model.

The bench retorted that it should not be wary of regulating one thing just because it cannot regulate anything. "Fair comment and equivalent duty of the right to a fair response…Journalists must be governed by certain principles," it stressed.

The court observed it is inclined to have a committee of five distinguished individuals of commendable stature to suggest certain principles to guide the electronic media. The matter will be heard next on September 17.

Next Story
Loading

Genetic Testing Market 2020 Trends And Review By Quantitative Analysis\, Comprehensive Landscape\, Current And Future Growth By Forecast To 2024

Tulsi And Ashwagandha Green Tea May Help Beat Stress And Anxiety - Experts Reveal - NDTV Food

Tulsi And Ashwagandha Green Tea May Help Beat Stress And Anxiety - Experts Reveal

As per health experts around the world, herb and spice-infused tea (green, black or olong tea) have often been considered to be a natural remedy for several ailments.

Somdatta Saha  |  Updated: September 16, 2020 14:11 IST

Reddit
<i>Tulsi</i> And <i>Ashwagandha</i> Green Tea May Help Beat Stress And Anxiety - Experts Reveal

Tulsi and Ashwagandha are potent adaptogens and can be consumed in form of kadha or tea

Highlights
  • Tulsi is dubbed to maintain the cortisol hormone level (stress hormone)
  • Ashwagandha has anti-ageing and de-stressing properties
  • Green tea is known to have calming effects on our nerves

Every chai-lover will agree to this that there's hardly anything a cup of hot tea can't fix. From reconnecting with your friends and loved ones over chai to rejuvenating yourself at any time of the day, a perfectly brewed tea does it all! And if you wisely add some herbs and spices to it, then it might go a long way to benefit your health too. As per health experts around the world, herb and spice-infused tea (green, black or olong tea) have often been considered to be a natural remedy for several ailments. Two such popular traditional herbs are Tulsi (Holy Basil) and Ashwagandha (Indian Ginseng).

For the unversed, both Tulsiand Ashwagandha have been an important part of traditional medical practice since centuries. These herbs are potent adaptogens and can be consumed in form of kadha or tea. As per Macrobiotic Nutritionist and Health Practitioner Shilpa Arora ND, "Ashwagandhaand Tulsi help balance hormones. It is the root cause for stress, fluctuations of mood and weight gain. Imbalance in hormone also reduces body's energy levels."

We bring you a herbal tea recipe that includes Tulsi and Ashwagandha, along with green tea, which may do wonders for relieving stress and anxiety after a long tiring day.

Benefits Of Tulsi For Beating Stress:

Tulsiis dubbed to maintain the level of cortisol hormone (stress hormone) in the body. According to a recent study published in the Journal of Ayurveda and Integrative Medicine, basil is a potent source of antidepressant and anti-anxiety properties.

Also Read: Tulsi Haldi Dalchini Laung Kadha May Be The Ideal Drink To Have Right Now For Good Immunity

tulsi basil teaTulsi (or Holy Basil) is a rich source of antioxidants

Benefits Of Ashwagandha For Beating Stress:

According to Consultant Nutritionist Rupali Dutta, "This traditional herb has anti-ageing and de-stressing properties. It is used to fight depression, anxiety and boost cognitive functioning. In this regard, one must remember that the ashwagandharoots have several medicinal properties and one can consume the roots in various forms."

Also Read:Healthy Diet: This Moon Milk At Night May Help Induce Good Sleep

eua7pot8Ashwagandha also help to promote overall stamina

Benefits Of Green Tea For Beating Stress:

Benefit of green tea is no secret to the world. Other than improving metabolism, promoting weight loss and boosting immune system, it is also known to have calming effects on our nerves. It is enriched with Theanine that helps to beat stress and anxiety. A research by the University of Shizuoka, Japan, found that the students who consumed green tea consistently experienced lower levels of stress.

Also Read: Adding Cinnamon, Turmeric To Green Tea May Help Boost Immunity, Weight Loss And Overall Health

1k41kdjoGreen tea also helps aid weight loss and metabolism

How To Brew Tulsi-Ashwagandha Green Tea:

Ingredients:

1.5 cups of water

Half teaspoon Ashwagandha roots

3-4 Tulsi leaves

1 teaspoon green tea

Method:

Step 1. Boil the water for 2-3 minutes.

Step 2. Switch of the flame and add green tea, ashwagandha roots and Tulsi leaves. Close the lid and let it infuse for 10 minutes.

Step 3. Strain it in a cup and sip on.



Listen to the latest songs, only on JioSaavn.com



(Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.)

Comments

About Somdatta SahaExplorer- this is what Somdatta likes to call herself. Be it in terms of food, people or places, all she craves for is to know the unknown. A simple aglio olio pasta or daal-chawal and a good movie can make her day.

For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube.

Related Articles: